HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bailey, W. C. Articles by Tashkin, D. P. Search for Related Content PubMed PubMed Citation Articles by Bailey, W. C. Articles by Tashkin, D. P.

Pharmacologic Therapy

Novel Approaches for Chronic Obstructive Pulmonary Disease

¹ University of Alabama Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama; and ² David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California

Correspondence and requests for reprints should be addressed to William C. Bailey, M.D., UAB Lung Health Center, 620 South 20th Street, Suite NHB 104, Birmingham, AL 35249–7337. E-mail: wcbailey{at}uab.edu

ABSTRACT

Chronic obstructive pulmonary disease (COPD) is increasing in the United States and throughout the world. There have been a number of advances in the treatment of this disease within the last several decades, and these improved therapies continue to become available, making the prospects for the future encouraging. Bronchodilation is the treatment of choice, and we point out in this article the potential availability of many new bronchodilators. There will be several options in the ß₂-agonist and the anticholinergic categories for once-a-day preparations. There will also be a number of products combining these categories of bronchodilators and inhaled steroids, and the combination products will be available in once-a-day preparations. Also under development are several candidates for specific and effective antiinflammatory agents in COPD. It is likely that our ability to control the inflammation underlying COPD will be a reality in the future. Although many new cases of COPD are being diagnosed in former smokers, for patients who smoke, the most important treatment is smoking cessation. A number of new drugs are available, and more will be brought to market in the future. We have highlighted the details of this important area.

Key Words: chronic obstructive pulmonary disease • bronchodilators • therapy • antiinflammatory agents • smoking cessation

This article has been cited by other articles:

				J. Doukas, L. Eide, K. Stebbins, A. Racanelli-Layton, L. Dellamary, M. Martin, E. Dneprovskaia, G. Noronha, R. Soll, W. Wrasidlo, et al. Aerosolized Phosphoinositide 3-Kinase {gamma}/{delta} Inhibitor TG100-115 [3-[2,4-Diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a Therapeutic Candidate for Asthma and Chronic Obstructive Pulmonary Disease J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 758 - 765. [Abstract] [Full Text] [PDF]

				A. Punturieri, T. L. Croxton, G. G. Weinmann, and J. P. Kiley Chronic Obstructive Pulmonary Disease: A View from the NHLBI Am. J. Respir. Crit. Care Med., September 1, 2008; 178(5): 441 - 443. [Full Text] [PDF]